Amersham Biosciences and Thermo Electron to Provide Mass Spectrometry-based Solutions to the Proteomics Research Community.Business Editors PISCATAWAY, N J. and WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 5, 2003 Two leading suppliers to the life sciences industry: Amersham Biosciences, the life sciences business of Amersham plc Amersham plc was a UK pharmaceutical company, specializing in medical diagnostics and life science products. The company was formed in 1997 by merging Amersham International (U.K.), Pharmacia Biotech (Sweden) and Nycomed (Norway). (LSE LSE - Language Sensitive Editor :OSE OSE - Open Systems Environment , NYSE NYSE See: New York Stock Exchange :AHM AHM Automated Hacking Machines AHM All Hands Meeting AHM Academy for Healthcare Management AHM Atom Heart Mother (Pink Floyd album) AHM Airport Handling Manual AHM Acutely Hazardous Material AHM Anti-Helicopter Mine ), and Thermo Electron Thermo Electron Corporation (TMO (NYSE)) (incorporated 1956) is a major provider of analytical instruments and services for a variety of domains. Thermo has revenues of over $2 billion, and employs 11,000 people in 30 countries. Corporation, (NYSE:TMO TMO T-Mobile TMO The Mac Observer (website) TMO Timeout (Hekimian) TMO Tenant Management Organisation (UK) TMO Toprak Mahsulleri Ofisi ) announced today that they will jointly market and sell mass spectrometry-based proteomics solutions designed to help protein scientists worldwide in their critical life sciences research. Initially, the two companies will co-market Amersham Biosciences' Ettan(TM) MALDI-ToF Pro mass spectrometer and Thermo Electron's Finnigan line of ion trap mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. systems, including the ProteomeXTM, an integrated proteomics workstation. The collaboration will also leverage the strengths of both companies, combining Amersham Biosciences' knowledge of, presence, and infrastructure in the proteomics market with Thermo Electron's extensive technical know-how and sales, support, and service expertise. Subsequently, the two companies expect to collaborate in developing next-generation solutions specifically designed for proteomics applications, encompassing instruments, software, and reagents. "Collaborating with Thermo Electron will enhance our ability to offer complete and integrated solutions to the proteomics research community, customized to meet their needs," said Andrew Carr, president of Amersham Biosciences. "Combining the strengths of both companies will enable us to develop proteomics applications more quickly and efficiently." Marc N. Casper, president of Thermo Electron's Life and Laboratory Sciences sector, commented, "We are delighted to team up with Amersham Biosciences in this important collaboration, which will help us better serve protein laboratory customers. Our mass spectrometry expertise, coupled with Amersham's expertise in protein chemistries, will provide laboratories with best-in-class solutions to enable cutting-edge proteomics research." About Amersham Biosciences Amersham Biosciences, the life sciences business of Amersham plc, is a world leader in developing and providing integrated systems and solutions for disease research, drug development, and manufacture. Our sy stems are used to uncover the function of genes and proteins, for the discovery and development of drugs, and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America, and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com About Thermo Electron Leading the world in high-tech instruments, Thermo Electron Corporation helps life science, laboratory, and industrial customers advance scientific knowledge, enable drug discovery, improve manufacturing processes, and protect people and the environment with instruments, scientific equipment, and sample-in/knowledge-out solutions. Based in Waltham, Massachusetts, Thermo Electron has revenues of more than $2 billion, and employs approximately 11,000 people in 30 countries worldwide. For more information, visit www.thermo.com Thermo Electron Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading "Forward-Looking Statements" in the company's Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the fiscal quarter ended September 28, 2002. These include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change, dependence on customers that operate in cyclical industries, the effect of changes in governmental regulations, dependence on customers' capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. policies and government funding policies, integration and consolidation of the company's instrument businesses, implementation of the company's strategies for improving internal growth, the company's guarantee of obligations of a subsidiary that was spun off, the effect of exchange rate fluctuations on international operations, and potential impairment of goodwill. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion